🇺🇸 FDA
Company

Vera

Vera Therapeutics

VERA pharma USA

Quick answer

Vera is a pharma company (VERA) headquartered in BRISBANE, CA, USA with 14 tracked pipeline programs.

Pipeline (14)

project

Atacicept

Lupus Nephritis (LN)

Phase 3 · small_molecule · terminated

1 trials project

Atacicept

IgA Nephropathy

Phase 3 · mab · active

1 trials project

Immune Globulin 10% Intravenous Solution

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Phase 3 · small_molecule · active

1 trials project

Analogs, Prostaglandin E1

Covid19

Phase 2 · small_molecule · terminated

1 trials project

Atacicept

pMN

Phase 2 · small_molecule · active

1 trials project

Atacicept

IgA Nephropathy (IgAN)

Phase 2 · small_molecule · active

1 trials project

Atacicept 150 mg

IgA Nephropathy (IgAN)

Phase 2 · small_molecule · active

1 trials project

Capecitabine

Breast Cancer

Phase 2 · small_molecule · terminated

1 trials project

Genomically Directed Monotherapy

Malignant Neoplasm of Breast

Phase 2 · small_molecule · completed

1 trials project

MAU868

BK Virus Infection

Phase 2 · small_molecule · completed

1 trials project

NestaCell®

COVID-19 Pneumonia

Phase 2 · mab · completed

1 trials project

CYP2C19 genotyping

Myocardial Infarction

Approved · gene_therapy · completed

1 trials project

Experimental: Hyperslim

Venous Thromboembolism (VTE)

Approved · other · active

1 trials project

Nitazoxanide Tablets

COVID-19

Unknown · small_molecule · completed

1 trials

Drugs (2)

drug

avutometinib potassium

AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)

 drug

verard

VERARD

Patents (8)

patent

US 12403164

Lentiviral vector formulations

Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12403183

Factor VIII polypeptide formulations

Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12391750

Anti-C1S antibodies and methods of use thereof

Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12371747

Methods of reducing immunogenicity against factor VIII in individuals undergoing

Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12364774

Nucleic acid molecules and uses thereof for non-viral gene therapy

Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12268688

Compositions and methods of use for modified release minoxidil

Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12257288

Methods of inducing immune tolerance to clotting factors

Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12240917

Anti-complement C1s antibodies and uses thereof

Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)